Klein Lawyers, together with co-counsel The Pihl Law Corporation (www.pihl.ca/), have filed a class action on behalf of Gabrielle Marcano and Lyle Folkestad for British Columbia residents who used the bisphosphonate drugs Fosamax, Didrocal and Actonel.
Bisphosphonates are prescription drugs that are used to increase bone density in patients with osteoporosis. However, they have also been known to lead to bone death in the jawbone, a condition known as osteonecrosis or atypical femur fracture. This lawsuit alleges that the defendants, Merck and Proctor & Gamble, failed to disclose this serious side effect to patients and their physicians.
A Canada-Wide Settlement Agreement has been signed on behalf of the Plaintiffs and the defendant Merck Frosst, the makers of Fosamax and/or Fosavance.
The settlement applies to:
(a) All persons in Canada who were prescribed, purchased or used any Bisphosphonate, such as Fosamax and/or Fosavance (including their estates) before October 6, 2015;
(b) All persons who by reason of his or her relationship to a member of the class described in paragraph (a) are entitled to make claims under any Derivative Claim Statute as a result of the death or personal injury of a class member.
Litigation against the manufacturers of Didrocal and Actonel continues.
Settlement approval hearings have been scheduled in the Saskatchewan Court on June 17, 2016, in the Quebec Court on June 30, 2016 and in the Ontario Court on July 8, 2016.
If you ingested Fosamax/Fosavance and have suffered from an atypical femur fracture, osteonecrosis of the jaw, or at least 6 consecutive weeks of exposed bone, or at least 8 consecutive weeks of non-healing of an extraction socket or other oral or dental surgical site please telephone us at 604-874-7171 or toll free at 1-800-468-4466 or email us at firstname.lastname@example.org or fill out our Do You Qualify Form online and a member of Klein Lawyers will contact you.
For more information: